Sirukumab Not Recommended for RA on Mortality Concerns

14:45 EDT 2 Aug 2017 | Medscape

An FDA panel voted not to recommend sirukumab for adults with moderate-to-severe rheumatoid arthritis because of increased mortality in patients who took the drug in clinical trials.
Medscape Medical News

Original Article: Sirukumab Not Recommended for RA on Mortality Concerns


More From BioPortfolio on "Sirukumab Not Recommended for RA on Mortality Concerns"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...